Factors associated with placebo response in depression trials

A systematic review of published meta-analyses (1990–2017)

J.H. Schoemaker, S. Kilian, R. Emsley, A.J.J.M. Vingerhoets

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Background:
Placebo response is common in patients with major depressive disorder (MDD) and decreases the likelihood of demonstrating drug superiority over placebo in a randomized, controlled trial (RCT). This paper aims to review the collective evidence for particular patient characteristics and trial features being associated
with placebo response in MDD.
Methods:
MEDLINE/PubMed publication database and Cochrane Library were searched for meta-analyses of placebo response in MDD, published in English from January 1990 to December 2017. The evidence for factors predicting a low or high placebo response was tabulated and weighted on the basis of methods, results, and quality of supporting studies.
Results:
We identified 58 papers, examining the possible association of 40 different factors with placebo response in MDD. Research methods varied considerably across articles so that our reporting remained descriptive. The evidence for any factor being associated with placebo response in MDD appeared very weak to weak.
Limitations:
Since none of the pooled analyses that we included could be regarded as a meta-analysis in its strict sense, and analytical approaches varied considerably, the current work is descriptive only, and without formal statistical analysis.
Conclusions:
Despite 25 years of pooling data from RCTs in MDD, there is no single factor for which strong evidence exists that it influences placebo response.
Original languageEnglish
Pages (from-to)12-21
JournalNeurology, Psychiatry and Brain Research
Volume30
DOIs
Publication statusPublished - 2017

Fingerprint

Major Depressive Disorder
Placebos
Depression
PubMed
MEDLINE
Libraries
Databases
Pharmaceutical Preparations

Cite this

@article{c06ef771062e443bb285febb51aa106c,
title = "Factors associated with placebo response in depression trials: A systematic review of published meta-analyses (1990–2017)",
abstract = "Background: Placebo response is common in patients with major depressive disorder (MDD) and decreases the likelihood of demonstrating drug superiority over placebo in a randomized, controlled trial (RCT). This paper aims to review the collective evidence for particular patient characteristics and trial features being associatedwith placebo response in MDD.Methods: MEDLINE/PubMed publication database and Cochrane Library were searched for meta-analyses of placebo response in MDD, published in English from January 1990 to December 2017. The evidence for factors predicting a low or high placebo response was tabulated and weighted on the basis of methods, results, and quality of supporting studies.Results: We identified 58 papers, examining the possible association of 40 different factors with placebo response in MDD. Research methods varied considerably across articles so that our reporting remained descriptive. The evidence for any factor being associated with placebo response in MDD appeared very weak to weak.Limitations: Since none of the pooled analyses that we included could be regarded as a meta-analysis in its strict sense, and analytical approaches varied considerably, the current work is descriptive only, and without formal statistical analysis.Conclusions: Despite 25 years of pooling data from RCTs in MDD, there is no single factor for which strong evidence exists that it influences placebo response.",
author = "J.H. Schoemaker and S. Kilian and R. Emsley and A.J.J.M. Vingerhoets",
year = "2017",
doi = "10.1016/j.npbr.2018.04.002",
language = "English",
volume = "30",
pages = "12--21",
journal = "Neurology, Psychiatry and Brain Research",
issn = "0941-9500",
publisher = "Elsevier GmbH",

}

Factors associated with placebo response in depression trials : A systematic review of published meta-analyses (1990–2017). / Schoemaker, J.H.; Kilian, S.; Emsley, R.; Vingerhoets, A.J.J.M.

In: Neurology, Psychiatry and Brain Research, Vol. 30, 2017, p. 12-21.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Factors associated with placebo response in depression trials

T2 - A systematic review of published meta-analyses (1990–2017)

AU - Schoemaker, J.H.

AU - Kilian, S.

AU - Emsley, R.

AU - Vingerhoets, A.J.J.M.

PY - 2017

Y1 - 2017

N2 - Background: Placebo response is common in patients with major depressive disorder (MDD) and decreases the likelihood of demonstrating drug superiority over placebo in a randomized, controlled trial (RCT). This paper aims to review the collective evidence for particular patient characteristics and trial features being associatedwith placebo response in MDD.Methods: MEDLINE/PubMed publication database and Cochrane Library were searched for meta-analyses of placebo response in MDD, published in English from January 1990 to December 2017. The evidence for factors predicting a low or high placebo response was tabulated and weighted on the basis of methods, results, and quality of supporting studies.Results: We identified 58 papers, examining the possible association of 40 different factors with placebo response in MDD. Research methods varied considerably across articles so that our reporting remained descriptive. The evidence for any factor being associated with placebo response in MDD appeared very weak to weak.Limitations: Since none of the pooled analyses that we included could be regarded as a meta-analysis in its strict sense, and analytical approaches varied considerably, the current work is descriptive only, and without formal statistical analysis.Conclusions: Despite 25 years of pooling data from RCTs in MDD, there is no single factor for which strong evidence exists that it influences placebo response.

AB - Background: Placebo response is common in patients with major depressive disorder (MDD) and decreases the likelihood of demonstrating drug superiority over placebo in a randomized, controlled trial (RCT). This paper aims to review the collective evidence for particular patient characteristics and trial features being associatedwith placebo response in MDD.Methods: MEDLINE/PubMed publication database and Cochrane Library were searched for meta-analyses of placebo response in MDD, published in English from January 1990 to December 2017. The evidence for factors predicting a low or high placebo response was tabulated and weighted on the basis of methods, results, and quality of supporting studies.Results: We identified 58 papers, examining the possible association of 40 different factors with placebo response in MDD. Research methods varied considerably across articles so that our reporting remained descriptive. The evidence for any factor being associated with placebo response in MDD appeared very weak to weak.Limitations: Since none of the pooled analyses that we included could be regarded as a meta-analysis in its strict sense, and analytical approaches varied considerably, the current work is descriptive only, and without formal statistical analysis.Conclusions: Despite 25 years of pooling data from RCTs in MDD, there is no single factor for which strong evidence exists that it influences placebo response.

U2 - 10.1016/j.npbr.2018.04.002

DO - 10.1016/j.npbr.2018.04.002

M3 - Article

VL - 30

SP - 12

EP - 21

JO - Neurology, Psychiatry and Brain Research

JF - Neurology, Psychiatry and Brain Research

SN - 0941-9500

ER -